Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.814
EU - Europa 2.469
AS - Asia 1.278
AF - Africa 6
SA - Sud America 5
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.719
IE - Irlanda 602
IT - Italia 449
SG - Singapore 422
CN - Cina 389
SE - Svezia 385
DE - Germania 363
HK - Hong Kong 301
RU - Federazione Russa 297
GB - Regno Unito 110
CA - Canada 91
UA - Ucraina 87
IN - India 51
FI - Finlandia 45
AT - Austria 36
VN - Vietnam 35
DK - Danimarca 32
TR - Turchia 25
BE - Belgio 17
FR - Francia 17
ID - Indonesia 17
JP - Giappone 14
IR - Iran 8
NL - Olanda 8
PL - Polonia 7
KR - Corea 6
BR - Brasile 4
ES - Italia 3
RO - Romania 3
AM - Armenia 2
AU - Australia 2
BD - Bangladesh 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
EG - Egitto 2
EU - Europa 2
MU - Mauritius 2
MX - Messico 2
SA - Arabia Saudita 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
CL - Cile 1
GR - Grecia 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
Totale 10.577
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.270
Fairfield 846
Dublin 594
Ashburn 555
Woodbridge 480
Wilmington 415
Seattle 383
Chandler 360
Singapore 337
Cambridge 320
Houston 315
Hong Kong 289
Frankfurt am Main 256
Princeton 246
New York 241
Jacksonville 162
Altamura 120
Lawrence 117
Beijing 97
Shanghai 90
San Diego 69
Santa Clara 69
Milan 68
Dearborn 60
Andover 44
Toronto 44
Vienna 34
Boardman 33
Nanjing 30
Helsinki 29
London 29
Guangzhou 26
Hangzhou 26
Turin 25
Ottawa 24
Dallas 23
Falls Church 23
Washington 22
Pune 21
Norwalk 18
Brussels 17
Dong Ket 17
Jakarta 17
Redmond 13
Rome 13
Tianjin 13
Lachine 12
Torre Del Greco 12
Hebei 11
Jinan 11
Munich 11
Tappahannock 10
Los Angeles 9
Chicago 8
Perugia 8
Phoenix 8
Zhengzhou 8
Fremont 7
Lissone 7
Edmonton 6
Kilburn 6
Kowloon 6
Mountain View 6
Nanchang 6
Shenyang 6
Torino 6
Carignano 5
Genoa 5
Lodz 5
Mumbai 5
Ningbo 5
Prescot 5
San Mateo 5
Bari 4
Desio 4
Hefei 4
Laurel 4
New Bedfont 4
Tokyo 4
Bologna 3
Bonndorf 3
Broni 3
Camogli 3
Changchun 3
Huizen 3
Jiaxing 3
Kocaeli 3
Kunming 3
Lappeenranta 3
Montréal 3
Sacramento 3
Seoul 3
Seregno 3
Suwon 3
Wuhan 3
Aci Catena 2
Acton 2
Amsterdam 2
Atlanta 2
Beaverton 2
Totale 8.581
Salva come PNG Salva come JPEG
Nome #
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 247
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 246
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 234
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 229
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 227
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 217
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 214
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 189
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 188
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 182
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 179
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 174
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 174
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 163
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 161
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 154
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 149
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 140
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 138
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 135
When progressive dysphagia could be related to an “old friend” – a case report 134
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 133
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 124
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 123
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 122
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 121
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 120
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 109
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 108
Novel cytotoxic chemotherapies in small cell lung carcinoma 106
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 100
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 99
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 98
Drugs ten years later: epirubicin 92
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 91
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 91
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 90
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 89
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 89
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 88
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 88
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 86
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 85
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 83
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 83
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 81
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 81
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 80
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 80
Focus on nivolumab in NSCLC 80
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 79
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 77
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 77
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 77
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 76
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 76
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 75
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 75
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 74
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 73
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 73
Oxaliplatin doublets in non-small cell lung cancer: A literature review 72
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 72
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 72
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 72
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 70
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 70
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 69
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 69
Pilot study with adriamycin and ifosfamide in small cell lung cancer 69
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 68
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 65
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 64
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 64
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 64
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 63
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 63
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 63
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 63
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 62
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 61
Esophageal carcinoma: radiochemotherapy 61
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 61
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 61
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 60
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 60
Combined radiation and chemotherapy in esophageal cancer 60
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 60
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 59
Radiologic examination in assessing the response to chemoradiotherapy of esophageal spinocellular carcinoma 58
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial 57
Isolated cardiac metastasis from squamous cell esophageal cancer 57
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 57
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 56
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 56
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial 54
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 54
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 54
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 54
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset 54
Totale 9.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.236
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.985 0 0 36 40 59 95 126 677 399 244 229 80
2020/20212.510 132 133 315 232 129 180 287 321 213 215 175 178
2021/20221.198 103 150 148 69 38 84 78 61 64 53 94 256
2022/20231.860 271 625 124 125 82 300 32 97 129 21 29 25
2023/20241.845 31 36 57 57 269 493 374 99 205 14 17 193
2024/2025884 218 491 175 0 0 0 0 0 0 0 0 0
Totale 11.139